For the quarter ending 2025-09-30, ZNTL had $1,473K increase in cash & cash equivalents over the period. -$26,963K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Consolidated net loss | -26,691 | -75,153 |
| Depreciation and amortization | 160 | 422 |
| Fixed asset impairment | 0 | 1,152 |
| Share-based compensation | 4,828 | 12,772 |
| Gain on disposal of equipment | 103 | 531 |
| Non-cash impact of license revenue | 0 | 0 |
| Non-cash recognized gain on mark-to-market of equity securities | 3,470 | -2,383 |
| Accretion of discounts on marketable securities, net | 517 | 1,815 |
| Deconsolidation of variable interest entity | 0 | 0 |
| Contracts receivable | 0 | -5,000 |
| Prepaid expenses and other assets | -679 | -3,012 |
| Accounts payable and accrued liabilities | -1,976 | -14,607 |
| Operating lease right-of-use assets and liabilities, net | 127 | 21 |
| Net cash used in operating activities | -26,963 | -67,344 |
| Purchases of marketable securities | 49,534 | 59,716 |
| Proceeds from maturities of marketable securities | 60,000 | 130,000 |
| Proceeds from sale of marketable equity securities | 17,855 | - |
| Proceeds from sale of property and equipment | 0 | 569 |
| Purchases of property and equipment | 0 | 0 |
| Net cash provided by investing activities | 28,321 | 70,853 |
| Proceeds from issuance of common stock under equity incentive plans | 115 | 189 |
| Net-settlement of restricted stock unit vesting | 0 | 0 |
| Net cash provided by financing activities | 115 | 189 |
| Net increase in cash, cash equivalents and restricted cash | 1,473 | 3,698 |
| Cash and cash equivalents at beginning of period | 36,528 | - |
| Cash and cash equivalents at end of period | 41,699 | - |
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)